GLP-1 Market
LLY $1351.12 ▼ -2.3% NVO $38.87 ▼ -1.4% PFE $27.54 ▼ -1.9% VKTX $25.84 ▼ -1.3% KLRA $11.58 ▼ -1.8% GPCR $17.12 ▼ -1.4% RHHBY $58.99 ▼ -0.9%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Sodium Zirconium Cyclosilicate

Company
AstraZeneca
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
5 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

5 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 20, 2026

Find a Clinical Trial Near Me

See recruiting studies for Sodium Zirconium Cyclosilicate and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT03813407

    An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia

    Not yet reported AstraZeneca 140 participants Est. completion 2030-02-21 70 sites Stand-alone
    Other conditions: Hyperkalaemia
    View official trial listing →
  • Recruiting NCT NCT06578078

    A Clinical Trial to Define the Best Strategy for the Management of Heart Failure in Elderly Patients

    Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 94 participants Est. completion 2026-12-30 6 sites Stand-alone
    Heart failureChronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT06578533

    Keeping RAASi Treatment With Optimal Potassium Control

    Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 78 participants Est. completion 2027-07-30 5 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07029503

    Swedish Cardiac And Renal Failure Study-1

    Not yet reported Karolinska Institutet 40 participants Est. completion 2027-10 1 site Stand-alone
    Heart failureChronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07944378

    A Study Evaluating the Safety and Effectiveness of Lokelma in Indian Patients With Hyperkalaemia

    Not yet reported AstraZeneca 120 participants Est. completion 2027-10-30 4 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT02088073

    Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

    Not yet reported ZS Pharma, Inc. 258 participants Est. completion 2015-01-31 46 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT02107092

    Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

    Not yet reported ZS Pharma, Inc. 123 participants Est. completion 2015-08-31 49 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT02163499

    Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

    Not yet reported ZS Pharma, Inc. 751 participants Est. completion 2016-11-30 50 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT02875834

    A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia

    Not yet reported AstraZeneca 267 participants Est. completion 2018-02-14 45 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT03127644

    ZS Ph2/3 Dose-response Study in Japan

    Not yet reported, Not yet reported AstraZeneca 103 participants Est. completion 2018-02-23 25 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT03172702

    Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

    Not yet reported AstraZeneca 150 participants Est. completion 2019-07-06 42 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT03283267

    A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

    Not yet reported AstraZeneca 22 participants Est. completion 2017-11-23 1 site Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT03303521

    A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.

    Not yet reported AstraZeneca 196 participants Est. completion 2018-11-07 53 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT03337477

    A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

    Not yet reported AstraZeneca 70 participants Est. completion 2018-12-21 25 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT03528681

    A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.

    Not yet reported AstraZeneca 270 participants Est. completion 2022-09-15 66 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Terminated NCT NCT03532009

    Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure

    Not yet reported AstraZeneca 182 participants Est. completion 2020-05-22 76 sites Stand-alone
    Heart failure
    View official trial listing →
  • Status unknown NCT NCT04063930

    The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia

    Not yet reported Steno Diabetes Center Copenhagen 20 participants Est. completion 2021-12 1 site
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04207203

    Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study

    Not yet reported Karolinska Institutet 26 participants Est. completion 2023-05-10 1 site
    Chronic kidney disease Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT04217590

    Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects

    Not yet reported AstraZeneca 134 participants Est. completion 2022-01-03 36 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT04566653

    Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

    AstraZeneca 147 participants Est. completion 2022-01-12 18 sites
    Heart failureChronic kidney disease
    View official trial listing →
  • Terminated NCT NCT04585542

    Comparison of Potassium Binders in the ER

    Not yet reported University of California, Irvine 37 participants Est. completion 2025-01-31 1 site Stand-alone
    Other conditions: Acute Hyperkalemia, Oral Potassium Binders
    View official trial listing →
  • Completed NCT NCT04676646

    Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

    Not yet reported AstraZeneca 366 participants Est. completion 2024-07-15 89 sites Stand-alone
    Heart failure Other conditions: Hyperkalaemia
    View official trial listing →
  • Terminated NCT NCT04727528

    Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

    Not yet reported AstraZeneca 39 participants Est. completion 2022-09-14 30 sites Stand-alone
    Chronic kidney disease Other conditions: Hyperkalaemia, Metabolic Acidosis
    View official trial listing →
  • Status unknown NCT NCT04727840

    Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

    Not yet reported Brigham and Women's Hospital 20 participants Est. completion 2022-01-15 1 site
    Chronic kidney disease Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT04788641

    Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects

    Not yet reported AstraZeneca 62 participants Est. completion 2021-09-16 1 site Stand-alone
    Other conditions: Hyperkalaemia
    View official trial listing →
  • Active, not recruiting NCT NCT04789239

    OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure

    Not yet reported Michael Fu 110 participants Est. completion 2025-12-31 2 sites Stand-alone
    Heart failure Other conditions: Hyperkalemia
    View official trial listing →
  • Terminated NCT NCT04847232

    Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

    Not yet reported AstraZeneca 2690 participants Est. completion 2024-03-07 340 sites Stand-alone
    Other conditions: Hyperkalemia
    View official trial listing →
  • Terminated NCT NCT04983979

    The ORTIZ Study: Optimising RASi Therapy With SZC

    Not yet reported Barts & The London NHS Trust 18 participants Est. completion 2023-05-16 1 site Stand-alone
    Chronic kidney diseaseType 2 diabetes Other conditions: Hyperkalemia
    View official trial listing →
  • Terminated NCT NCT04997161

    Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia

    Not yet reported AstraZeneca 3 participants Est. completion 2021-11-17 1 site Stand-alone
    Other conditions: Hyperkalaemia
    View official trial listing →
  • Completed NCT NCT05004363

    Lokelma for RAAS Maximisation in CKD & Heart Failure.

    Not yet reported St George's, University of London 112 participants Est. completion 2024-07-01 1 site
    Chronic kidney diseaseHeart failure Other conditions: Hyperkalemia, ACE Inhibitor Induced Hyperkalaemia, Mineralocorticoid Resistant Hyperkalemia
    View official trial listing →
  • Terminated NCT NCT05056727

    A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

    Not yet reported AstraZeneca 1112 participants Est. completion 2024-02-07 276 sites Stand-alone
    Other conditions: Renal Insufficiency, Chronic, Hyperkalemia
    View official trial listing →
  • Completed NCT NCT05271266

    A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China

    AstraZeneca 1000 participants Est. completion 2023-12-06 27 sites
    Other conditions: Hyperkalaemia
    View official trial listing →
  • Completed NCT NCT05347693

    Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study

    Not yet reported AstraZeneca 186 participants Est. completion 2024-12-10 28 sites Stand-alone
    Chronic kidney disease Other conditions: Hyperkalaemia
    View official trial listing →
  • Completed NCT NCT05382988

    Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy

    Not yet reported Guangdong Provincial People's Hospital 62 participants Est. completion 2021-12 Stand-alone
    Other conditions: Sodium Zirconium Cyclosilicate, Hyperkalemia, Hyperparathyroidism, Secondary
    View official trial listing →
  • Completed NCT NCT05535920

    A Prospective, Randomized, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia

    Not yet reported NephroNet, Inc. 88 participants Est. completion 2024-04-01 5 sites
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT06029179

    SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

    Not yet reported Alexandria University 120 participants Est. completion 2024-12-15 1 site
    Other conditions: Hyperkalemia
    View official trial listing →
  • Completed NCT NCT06185660

    A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece

    AstraZeneca 125 participants Est. completion 2025-01-03 10 sites
    Other conditions: Hyperkalaemia
    View official trial listing →
  • Status unknown NCT NCT06365684

    Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4

    Not yet reported Leiden University Medical Center 16 participants Est. completion 2025-05-01 1 site Stand-alone
    Chronic kidney disease Other conditions: Hyperkalemia, Diet Modification, Sodium Zirconium Cyclosilicate
    View official trial listing →
  • Completed NCT NCT06635499

    VITALIZE.Use and Effectiveness of Sodium Zirconium Cyclosilicate (LokelmaTM) in the Real-world Setting in Spain

    AstraZeneca 232 participants Est. completion 2025-05-20 14 sites
    Other conditions: Hyperkalaemia
    View official trial listing →
  • Not yet recruiting NCT NCT06736184

    the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients

    Not yet reported Qianfoshan Hospital 100 participants Est. completion 2026-12-31 Stand-alone
    Chronic kidney disease Other conditions: Hypokalemia, Hyperkalemia, Myocardial Injury
    View official trial listing →
  • Not yet recruiting NCT NCT07576257

    OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension)

    Not yet reported Sahlgrenska University Hospital 110 participants Est. completion 2030-06-30
    Heart failure
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Sodium Zirconium Cyclosilicate, LOKELMA

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.